Burning Rock Biotech Limited logo

Burning Rock Biotech LimitedNASDAQ: BNR

Profile

Sector:

Healthcare

Country:

China

IPO:

12 June 2020

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$54.92 M
-96%vs. 3y high
36%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
29%vs. sector
-96%vs. 3y high
20%vs. sector

Price

regular market | 5 min ago
$5.35+$0.71(+15.37%)

Dividend

No data over the past 3 years
$18.84 M-$15.02 M

Analysts recommendations

Institutional Ownership

BNR Latest News

Burning Rock Announces Changes to Management and Board of Directors
globenewswire.com27 September 2024 Sentiment: NEUTRAL

GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Leo Li as a director from the Company's board of directors (the “Board”) and as the Company's chief financial officer, effective September 27, 2024.

Burning Rock Reports Second Quarter 2024 Financial Results
globenewswire.com22 August 2024 Sentiment: POSITIVE

GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024.

Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
globenewswire.com19 August 2024 Sentiment: NEGATIVE

GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained low volume of trading and liquidity in the ADSs on the LSE, and taking into account the costs associated with maintaining such listing in place, the Company is seeking the delisting and cancellation of admission to trading of the ADSs from the LSE (the “Delisting”).

Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
globenewswire.com30 May 2024 Sentiment: POSITIVE

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.

Burning Rock Reports First Quarter 2024 Financial Results
globenewswire.com29 May 2024 Sentiment: POSITIVE

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction.

Burning Rock Biotech Limited (BNR) Q3 2023 Earnings Call Transcript
Seeking Alpha30 November 2023 Sentiment: POSITIVE

Burning Rock Biotech Limited (NASDAQ:BNR ) Q3 2023 Earnings Call Transcript November 30, 2023 7:00 AM ET Company Participants Yusheng Han - Founder, Chairman and Chief Executive Officer Leo Li - CFO Joe Zhang - CTO Conference Call Participants Operator Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will, expect, anticipate, future, intends, plans, believes, estimates, target, confident and similar statements.

Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
GlobeNewsWire20 November 2023 Sentiment: POSITIVE

GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m.

Burning Rock Biotech Limited (BNR) Q2 2023 Earnings Call Transcript
Seeking Alpha31 August 2023 Sentiment: POSITIVE

Burning Rock Biotech Limited (NASDAQ:BNR ) Q2 2023 Earnings Conference Call August 31, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman and CEO Leo Li - CFO Conference Call Participants Operator Good morning, ladies and gentlemen. Thank you for standing by.

Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023
GlobeNewsWire04 August 2023 Sentiment: NEGATIVE

GUANGZHOU, China, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2023.

Burning Rock Biotech Limited (BNR) Q1 2023 Earnings Call Transcript
Seeking Alpha30 May 2023 Sentiment: NEUTRAL

Burning Rock Biotech Limited (NASDAQ:BNR ) Q1 2023 Earnings Conference Call May 30, 2023 8:00 AM ET Company Participants Yusheng Han - Founder, Chairman & CEO Leo Li - CFO Joe Zhang - CTO Conference Call Participants Alexis Yan - Morgan Stanley Operator Good day, and thank you, for standing by. Welcome to the Burning Rock's 2023 Q1 Earnings Conference Call.

What type of business is Burning Rock Biotech Limited?

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

What sector is Burning Rock Biotech Limited in?

Burning Rock Biotech Limited is in the Healthcare sector

What industry is Burning Rock Biotech Limited in?

Burning Rock Biotech Limited is in the Diagnostics & Research industry

What country is Burning Rock Biotech Limited from?

Burning Rock Biotech Limited is headquartered in China

When did Burning Rock Biotech Limited go public?

Burning Rock Biotech Limited initial public offering (IPO) was on 12 June 2020

What is Burning Rock Biotech Limited website?

https://www.brbiotech.com

Is Burning Rock Biotech Limited in the S&P 500?

No, Burning Rock Biotech Limited is not included in the S&P 500 index

Is Burning Rock Biotech Limited in the NASDAQ 100?

No, Burning Rock Biotech Limited is not included in the NASDAQ 100 index

Is Burning Rock Biotech Limited in the Dow Jones?

No, Burning Rock Biotech Limited is not included in the Dow Jones index

When was Burning Rock Biotech Limited the previous earnings report?

No data

When does Burning Rock Biotech Limited earnings report?

The next expected earnings date for Burning Rock Biotech Limited is 29 November 2024